Sign Up to like & get
recommendations!
0
Published in 2017 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2016.2923
Abstract: Nivolumab is a monoclonal antibody directed against PD1 (programmed cell death 1) that can improve survival in patients with metastatic melanoma. Such immune checkpoint inhibitors have been known to induce type 1 diabetes mellitus (T1D)…
read more here.
Keywords:
fulminant type;
type diabetes;
diabetes mellitus;
case fulminant ... See more keywords